Complete Genomics
19.05.2011 14:00
---------------------------------------------------------------------------
New Agreement Provides for Complete Genomics to Sequence 250 Samples for
Erasmus MC Studies Including Cancer and Congenital Malformations
MOUNTAIN VIEW, Calif., 2011-05-19 14:00 CEST (GLOBE NEWSWIRE) --
Complete Genomics Inc. (Nasdaq:GNOM), a complete human genome sequencing
company that has developed and commercialized an innovative DNA sequencing
platform, announced today an expansion of its collaboration with Erasmus
University Medical Center (Erasmus MC), based in Rotterdam, the Netherlands.
This agreement calls for Complete Genomics to sequence 250 DNA samples for
Erasmus MC research studies over the next 12 months. Samples will come from
patients with leukemia and other cancers and congenital malformations, such as
craniosynostosis. Erasmus MC is working with external collaborators, including
Sanquin Blood Supply Foundation, a not-for-profit organization that manages the
blood supply in the Netherlands, and various teams at the Academic Medical
Center of the University of Amsterdam to obtain some of the samples.
Erasmus MC and Complete Genomics are also collaborating in several other
research areas, which have not yet been disclosed. As part of the agreement,
Erasmus MC is also allowing Complete Genomics to use its bioinformatics
training center for customer training purposes. That center is ideally located
in the center of Europe.
'We decided to focus our research efforts with Complete Genomics on diseases
where the current technology has not been able to identify the genetic variants
responsible,' said Professor Dr. Peter J. van der Spek, head of bioinformatics
at Erasmus MC. 'Its complete human genome sequencing service will allow us to
study genetic variations at a higher resolution and greater sensitivity than
has been previously possible. We are optimistic that we will be able to obtain
answers to some of the scientific questions that have proven elusive to date.'
Dr. Clifford Reid, chairman, president and CEO of Complete Genomics, added, 'By
using our complete human genome sequencing service, Erasmus MC will be able to
obtain timely, high-quality data to further its research efforts without having
to maintain and update sequencing instruments of its own. We hope that by
furthering its understanding of the genetics of these complex diseases, Erasmus
MC can be at the forefront of developing better diagnostic screens that form
the basis for genetic testing in monogenetic diseases and targeted treatment
development for diseases such as cancer.'
'Since only 4 percent of the Dutch national healthcare budget is currently
spent on diagnostics and yet 72 percent of medical decisions depend on those
diagnostics, we expect this new technology to change the way patient
stratification is conducted for targeted treatments in the very near future in
the Netherlands,' van der Spek added.
Additional expertise in technology and data management is being co-developed
for this translational medicine project through strategic partnerships with
companies such as Ingenuity, Biobase, TIBCO/Spotfire, Oracle and VX Company.
About Complete Genomics
Complete Genomics is a complete human genome sequencing company that has
developed and commercialized an innovative DNA sequencing platform. The
Complete Genomics Analysis Platform (CGA? Platform) combines Complete Genomics'
proprietary human genome sequencing technology with our advanced informatics
and data management software. We offer this solution as an innovative,
end-to-end, outsourced service, CGA? Service, and provide customers with data
that is immediately ready to be used for genome-based research. Additional
information can be found at http://www.completegenomics.com.
The Complete Genomics logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8216
About Erasmus University Medical Center Rotterdam
Erasmus MC is the largest and one of the most authoritative scientific
University Medical Centers in Europe. More then 13,000 staff members work
within the core tasks of patient care, education, and scientific research on
the continuous improvement and enforcement of individual patient care and
social healthcare. They develop high-level knowledge, pass this on to future
professionals, and apply it in everyday patient care. Erasmus MC is part of the
Dutch Federation of University Medical Centers (NFU). See www.nfu.nl and
www.erasmusmc.nl
Forward-Looking Statements
Certain statements in this press release, including statements relating to the
ability of our customers to use the genome sequencing data that we provide to
them to develop better diagnostic tools and targeted therapies for diseases and
to change the way patient stratification is conducted for targeted disease
treatments are forward-looking statements that are subject to risks and
uncertainties. Readers are cautioned that these forward-looking statements are
based on management's current expectations, and actual results may differ
materially from those projected. The following factors, without limitation,
could cause actual results to differ materially from those in the
forward-looking statements: the usefulness of genomic data in identifying or
treating disease; the ability of our customers to successfully analyze the
genomic data we provide; and the ability of researchers to convert genomic data
into medically valuable information. More information on potential factors that
could affect the usefulness of the genomic data that we provide to our
customers is included in our Securities and Exchange Commission filings and
reports, including the risks identified under the section captioned 'Risk
Factors' in our Registration Statement on Form S-1 filed on May 18, 2010. We
disclaim any obligation to update information contained in these
forward-looking statements, whether as a result of new information, future
events or otherwise.
CONTACT: Complete Genomics Inc.
Jennifer Turcotte
Vice President of Marketing
(650) 943-2846
jturcotte@completegenomics.com
Waggener Edstrom Worldwide
Healthcare
Lisa Osborne
Account Director
(202) 261-7806
completegenomics@waggeneredstrom.com
News Source: NASDAQ OMX
19.05.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Complete Genomics
US
Phone:
Fax:
E-mail:
Internet:
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Erasmus University Medical Center Partners With Complete Genomics to Begin Developing Its Genomic Medicine Pipeline
| Source: EQS Group AG